Gold prices steady ahead of Fed decision; weekly weakness noted
Investing.com -- Pfizer (NYSE:PFE), along with other pharmaceutical companies, has engaged in discussions with the Trump administration regarding most-favored-nation pricing, according to Pfizer’s Chief Executive Albert Bourla. He made these comments at an industry conference on Monday.
The discussions have not yet resulted in any commitments. Bourla noted that the meetings have concentrated on general ideas and have not delved into specific details.
Last month, President Donald Trump issued an executive order with the goal of reducing the cost of branded medicines for U.S. consumers. The order aims to ensure that the United States, as the ’most favored nation’, pays the lowest price for prescription drugs compared to other developed nations. The meetings between Pfizer and the Trump administration are part of the ongoing efforts to implement this policy.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.